Experimental Study
Specific T cell immunotherapy against glioblastoma with mouse model
Zhang Jingwen, Yang Zixiao, Xu Yang, Qi Zengxin, Zhang Hongyi, Mao Ying, Hua Wei
Published 2018-12-08
Cite as Chin J Exp Surg, 2018,35(12): 2281-2283. DOI: 10.3760/cma.j.issn.1001-9030.2018.12.032
Abstract
ObjectiveTo investigate the feasibility and effectiveness of specific T cell immunotherapy against glioblastoma in vivo.
MethodsTotal tumor antigen (TTA) was extracted from GL261 cells and to sensitize the dentric cells (DCs) from C57BL/6 mice. T cells were co-cultured with maturated DCs and the cytotoxicity against glioma cells were analyzed. GL261 cells were intracranially implanted into 16 C57BL/6 mice. Eight were intravenously injected with specific T cells and the others were injected with PBS. A consecutive monitor was conducted with MR, and the subpopulation of T lymphocyte from mice blood was analyzed with flow cytometry. Draw the survival curves at the end.
ResultsWhen the effector-target (E∶T) ratio was 60∶1, the killing rate of effect T cells in matured DC group was (62.67±2.52)%, while the control group was (26.33±2.08)% (P=0.000). The ratio of CD8a/CD4 in mice peripheral blood after treated with T cells was 1.18±0.31, higher than that of the control group, which was 0.28±0.05 (P=0.047). MRI showed that tumors were significantly inhibited after specific T cell immunotherapy. The survival period of the control group was (22.63±2.38) d, there were 2 mouses died in the treatment group and the rest survived until the end of the experiment (80 d) (P=0.001). Through autopsy, we found that the control group died as tumor growth, and two of the treatment group which dead before the end of the experiment were also found tumor growth, we didn’t observe tumor among other mice of treatment group.
ConclusionTTA from GL261 could elicit specific adoptive T cell immunotherapy against glioma both in vitro and in vivo.
Key words:
T cell; Immunothreapy; Glioma; Dentric cells; Total tumor antigen
Contributor Information
Zhang Jingwen
Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China
Yang Zixiao
Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China
Xu Yang
Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China
Qi Zengxin
Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China
Zhang Hongyi
Department of Neurosurgery, Tangshan Gongren Hospital, Tangshan, 063001, China
Mao Ying
Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China
Hua Wei
Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, China
